Author:
Zhang Qi,Ren Hao,Ge Luqi,Zhang Wen,Song Feifeng,Huang Ping
Abstract
AbstractRenal cell carcinoma (RCC) is the second lethal urogenital malignancy with the increasing incidence and mortality in the world. Clear cell renal cell carcinoma (ccRCC) is one major subtype of RCC, which accounts for about 70 to 80% of all RCC cases. Although many innovative therapeutic options have emerged during the last few decades, the efficacy of these treatments for ccRCC patients is very limited. To date, the prognosis of patients with advanced or metastatic ccRCC is still poor. The 5-year survival rate of these patients remains less than 10%, which mainly attributes to the complexity and heterogeneity of the tumor microenvironment (TME). It has been demonstrated that long non-coding RNAs (lncRNAs) perform an indispensable role in the initiation and progression of various tumors. They mostly function as sponges for microRNAs (miRNAs) to regulate the expression of target genes, finally influence the growth, metastasis, apoptosis, drug resistance and TME of tumor cells. However, the role of lncRNA/miRNA/mRNA axis in the TME of ccRCC remains poorly understood. In this review, we summarized the biological function of lncRNA/miRNA/mRNA axis in the pathogenesis of ccRCC, then discussed how lncRNA/miRNA/mRNA axis regulate the TME, finally highlighted their potential application as novel biomarkers and therapeutic targets for ccRCC.
Funder
Zhejiang Province Natural Science Foundation of China
National Natural Science Foundation of China
Medical and Health Research Program of Zhejiang
Leading Talent of “Ten Thousand Plan” - National High-Level Talents Special Support Plan and the Science Technology Plan Project of Zhejiang Province
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference225 articles.
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.
3. Bahadoram S, Davoodi M, Hassanzadeh S, Bahadoram M, Barahman M, Mafakher L. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol. 2022;39(3):1.
4. Liu X, Hao Y, Yu W, Yang X, Luo X, Zhao J, Li J, Hu X, Li L, et al. Long non-coding RNA emergence during renal cell carcinoma tumorigenesis. Cellular Physiol Biochem. 2018;47(2):735–46.
5. Motzer R, Jonasch E, Agarwal N, Bhayani S, Bro W, Chang S, Choueiri T, Costello B, Derweesh I, Fishman M, et al. Kidney cancer, version 2 2017, NCCN clinical practice guidelines in oncology. J National Comprehen Cancer Net. 2017;15(6):804–34.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献